ArticleBasic and clinical neuroscience
The PCSK9 Protein Is Not Necessarily a Risk Factor for Major Depressive Disorder.
Article in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PCSK9 at the intersection of lipid metabolism, immunometabolism, and psychiatric disorders: A narrative review.Brain, behavior, & immunity - health · 2026Review
- Protein biomarkers for bipolar II disorder are correlated with affective cognitive performance.BMC psychiatry · 2025Article
- Association of proprotein convertase subtilisin/kexin type 9 protein and oxidative stress indicators in women with preeclampsia: A case-control study.International journal of reproductive biomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Major depressive disorder (MDD) is one of the common psychiatric disorders that is characterized by abnormal neurobiological responses. Proprotein convertase subtilisin/kexin 9 (PCSK9) is important in cholesterol homeostasis. Methods: This study aimed to investigate PCSK9 levels and oxidative stress with MDD disease. The study included 30 patients with MDD and 30 healthy controls. Their blood samples were collected in sterile tubes, and the serum PCSK9 concentration, superoxide dismutase (SOD), and glutathione peroxidase (GPx) activity were determined by ELISA kits. Total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA), and copper concentration were determined manually. There was a significant increase in PCSK9 levels in the patient group (P<0.05). Results: The receiver operating characteristic (ROC) curve with a sensitivity of 57% and specificity of 52% was 0.928 (95% CI, 0.86-0.996) for PCSK9 in the patient group (P<0.001). It was found that MDA (P=0.036) level was higher in the MDD group, but TAC (P=0.445) level, SOD (P=0.148), GPx (P=0.019) activities, and copper concentration were lower in the patient group compared with the control group. Conclusion: The study results confirm the relationship between oxidative stress and MDD and also suggest a link between PCSK9 and MDD disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.